We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Senseonics (SENS) Moves 5.3% Higher: Will This Strength Last?
Read MoreHide Full Article
Senseonics Holdings (SENS - Free Report) shares soared 5.3% in the last trading session to close at $7.33. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 26.1% gain over the past four weeks.
Senseonics Holdings scored a strong price increase on investors’ optimism surrounding the achievement of CE Mark approval for the Eversense 365 continuous glucose monitoring (CGM) system. Eversense 365 is the world’s first and only oneyear CGM. It has been cleared as an integrated CGM system in the United States, indicating that it can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system.
This medical technology company is expected to post quarterly loss of $0.43 per share in its upcoming report, which represents a year-over-year change of -7.5%. Revenues are expected to be $14.2 million, up 71.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Senseonics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SENS going forward to see if this recent jump can turn into more strength down the road.
Senseonics is a member of the Zacks Medical Info Systems industry. One other stock in the same industry, Talkspace, Inc. (TALK - Free Report) , finished the last trading session 3.6% higher at $4.04. TALK has returned 7.4% over the past month.
Talkspace's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.02. Compared to the company's year-ago EPS, this represents a change of +100%. Talkspace currently boasts a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Senseonics (SENS) Moves 5.3% Higher: Will This Strength Last?
Senseonics Holdings (SENS - Free Report) shares soared 5.3% in the last trading session to close at $7.33. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 26.1% gain over the past four weeks.
Senseonics Holdings scored a strong price increase on investors’ optimism surrounding the achievement of CE Mark approval for the Eversense 365 continuous glucose monitoring (CGM) system. Eversense 365 is the world’s first and only oneyear CGM. It has been cleared as an integrated CGM system in the United States, indicating that it can integrate with compatible medical devices, including insulin pumps as part of an automated insulin delivery (AID) system.
This medical technology company is expected to post quarterly loss of $0.43 per share in its upcoming report, which represents a year-over-year change of -7.5%. Revenues are expected to be $14.2 million, up 71.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Senseonics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SENS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Senseonics is a member of the Zacks Medical Info Systems industry. One other stock in the same industry, Talkspace, Inc. (TALK - Free Report) , finished the last trading session 3.6% higher at $4.04. TALK has returned 7.4% over the past month.
Talkspace's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.02. Compared to the company's year-ago EPS, this represents a change of +100%. Talkspace currently boasts a Zacks Rank of #3 (Hold).